|
|
|
|
|
Last Trade
|
Last Trade:
$1.34
|
Change:
-0.07 (-4.97%)
|
Trade Time:
May 26
|
Market Cap:
$4.08M
|
|
|
|
|
|
|
Description of Business
|
|
Timber Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company
focused on the development and commercialization of treatments for orphan
dermatologic diseases. Our investigational therapies have proven
mechanisms-of-action backed by decades of clinical experience and
well-established CMC (chemistry, manufacturing and control) and safety profiles.
We are initially focused on developing non-systemic treatments for rare
dermatologic diseases including congenital ichthyosis ("CI"), including X-linked
recessive CI ("XLRI") and autosomal recessive CI ("ARCI") and other sclerotic
skin diseases. Our lead late-stage program is TMB-001. TMB-003 is our earliest
stage program.
|
|
|
|